Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216723
Status:
COMPLETED
Last Update Posted:
2013-10-23
First Post:
2005-09-14
Brief Title:
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
Sponsor:
Korea Otsuka Pharmaceutical Co Ltd
Organization:
Korea Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenteropen-labelprospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder
Detailed Description:
This is a multicenteropen-labelprospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder
Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physicians assessment
Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physicians assessment
This study will be continued for 6 years The final report of Aripiprazole PMS will be submitted to KFDA on December 28 2009
Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physicians assessment
Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physicians assessment
This study will be continued for 6 years The final report of Aripiprazole PMS will be submitted to KFDA on December 28 2009
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None